SELLAS Life Sciences Group, Inc. (SLS) reported a narrower net loss of $26.86 million for the full year 2025, improving from $30.88 million in 2024, while providing updates on its clinical pipeline. The company is advancing its lead candidate, Galinpepimut-S (GPS), through a pivotal Phase 3 trial for Acute Myeloid Leukaemia (AML) and has initiated an expansion cohort for its CDK9 inhibitor, SLS009, in newly diagnosed AML patients.
This progress is significant for SELLAS as a successful outcome from the REGAL trial could establish GPS as a leading immunotherapeutic option, potentially driving stock performance and investor interest. The firm also strengthened its financial position, ending 2025 with $71.8 million in cash, bolstered by an additional $42.6 million from warrant exercises in early 2026.
With 2026 poised to be a critical year for SELLAS, market professionals should monitor the developments closely. For a deeper dive into SELLAS’ financials and clinical advancements, I recommend checking out the full article.
Source: nasdaq.com